Collaboration
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3
REGN
FY2026 Q2
개선
Regeneron Pharmaceuticals, Inc. 실적 발표
Buzzberg 분석
Sanofi collaboration repayment complete, boosting revenue from Q3.
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
Buzzberg 분석 Sanofi collaboration repayment complete, boosting revenue from Q3. Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo. 전체 분석 보기분석 접기
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
- Dupixent net sales reached $6 billion, up 38%, with Eylea HD up 52% to $596 million.
- Libtayo net sales up 29% to $489 million, capturing 20% of new-to-brand lung cancer share.
- CFO notes full Sanofi development balance repayment will boost Sanofi collaboration revenue from Q3 onwards.
매출$4.2907B+19% 전분기 대비
주당순이익(EPS)$14.29+51% 전분기 대비
매출총이익률86.56%보고값
영업이익률33.11%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Regulatory
ILEA-HD pre-filled syringe approval targeted by year-end.
Pipeline
Long-acting IL-13 antibody shows prolonged half-life, expedited path.
핵심 내용 3개 더 보기
Partnerships
Discussions with Sanofi to expand collaboration on follow-on assets.
Obesity
Obesity portfolio advancing with Phase III starts expected.
Pipeline
Factor XI program to initiate remaining Phase III studies this year.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $4.2907B | +19% 전분기 대비 |
| 주당순이익(EPS) | $14.29 | +51% 전분기 대비 |
| 매출총이익률 | 86.56% | 보고값 |
| 영업이익률 | 33.11% | 보고값 |
| 잉여현금흐름 | $0.3343B | 보고값 |
| 자본지출 | $0.2402B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 잉여현금흐름 | FY2026 | $1.4B | $1.4B | 제시 |
AI, 자본지출 및 수요 분석
경영진 분석
Upbeat
Management highlighted strong growth across key products, reiterated confidence in the pipeline and partnerships, and emphasized a broad, diversified portfolio and disciplined capital allocation.
투자 및 생산능력
The company noted a temporary interruption in bulk manufacturing production at its Limerick, Ireland facility, which resumed to normal levels as of the end of the second quarter. No other significant capital expenditure or capacity investment details were discussed.
아래에 언급된 기업 2개 모두 표시
기업발표 이후 수익률
파트너
파트너
Chris Fenimore
Bayesian product royalties and profit share contributed a significant increase to other revenue, indicating underlying strength from the Bayer collaboration's portfolio.
근거
“royalty income from Alaris combined with our share of profits from Arculus totaled $157 million, an increase of 44% versus the prior year.”
파트너
Dr. Leonard Schleifer
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.
근거
“productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Depixent follow-on programs.”
외부 신호
공급망 알파 · 3발표 이후 수익률
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits.
근거
“Given full repayment of the Sanofi development balance, Starting in the third quarter, we expect Sanopi Collaboration Revenue to step up as we record our full share of collaboration profits.”
After two consecutive quarters of pressure, Regeneron's Limerick facility resumed normal production levels, alleviating unabsorbed manufacturing costs.
근거
“Production at this facility resumed to normal levels as of the end of the second quarter.”
ILI-A HD sequentially declined 13-15% due to conversions and biosimilars, while HD is expected to grow low-to-mid teens on the back of share gains.
근거
“we expect sequential quarterly demand declines in the low to mid-teens due to the factors mentioned as well as additional competition primarily from multiple Flippercept 2 mg biosimilar launches.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 2개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.